Board of Directors
REPROCELL Board Of Directors Biographies
Chikafumi Yokoyama, Ph.D.
Chief Executive Officer
Dr. Yokoyama joined REPROCELL Inc. in 2004 as a general manager of the business development division and became Chief Executive Officer in 2005. He has been responsible for new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, Dr Yokoyama worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, as an R&D leader. He received his Ph.D. in chemistry from Tokyo University in 1996.
Mr. Daisuke Usui has global experience in key business position of medical and biotech companies in mature and emerging markets. His diverse background includes various roles managing finance, sales and marketing, supply chain, and launching new products. Prior to joining REPROCELL, Daisuke was responsible for sales and commercial activities in Asia Pacific with HOYA Surgical Optics, in addition to being an executive manager for its subsidiary in India. Daisuke holds a bachelor of arts (International Studies) from Tsukuba University (Japan).
Mr. Koji Kuchiishi joined REPROCELL in February 2017 as the Chief Business Development Officer and the Head of Medical Business and has become an executive director in June 2017.
He has seven years of entrepreneurial experience at Cyfuse Biomedical K.K and a strong personal network in the regenerative medicine industry. His diverse expertise includes Corporate Strategy, Open Innovation, Intellectual Property, Industry–Academia Collaboration, Product Development, and Venture Financing.
Since he joined REPROCELL, he has been leading the new Medical Business to drive long term growth of the company by developing products and services that accelerate breakthrough medical technologies and therapies.
Koji graduated from the department of science and engineering at Keio University, Tokyo with a Bachelor of Science degree.
Mr. Yamakawa has been a non-executive director of REPROCELL since 2008. He is the CEO of HIBIKI Partners, a consulting company, and a BOD member of some listed companies. Having graduated from Waseda University in economics, he started his career as a venture capitalist at Nippon Life Insurance. After experiencing directorship of corporate planning at Innotech Corporation, Mr. Yamakawa joined Sosei Co. Ltd. in 2001 and succeeded in its IPO and M&A as a representative executive officer and CFO.
REPROCELL Group CEO
CEO, REPROCELL USA Inc
Rama is the CEO of REPROCELL USA. Rama Modali is also the founder and president of BioServe. For years, Rama has spearheaded our efforts to develop and provide advanced molecular biology services to pharmaceutical, academic and government institutions. With more than 30 years’ experience in molecular biology, Rama continues to guide successful growth, international expansion and provision of cutting-edge scientific applications to enhance our customers’ research.
Prior to becoming REPROCELL USA’s CEO and founding BioServe, Rama worked as a molecular biologist at the National Institutes of Health and National Cancer Institute. He has over 32 peer reviewed research publications.
David Bunton, Ph.D.
CEO, REPROCELL Europe Ltd
Dr. David Bunton is CEO of REPROCELL Europe, a life sciences company based in Glasgow, UK, and a subsidiary of REPROCELL Inc. Having founded a human tissue assay service company (Biopta Ltd.) in 2002, Dr. Bunton later took over as the CEO of the conjoint REPROCELL Europe business after the acquisition of Biopta by REPROCELL. The company remains focused on the use of human fresh tissues, 3D models and the use of iPSCs to better characterize drug efficacy and inter-patient variability in drug responses.
Previously a Lecturer at Glasgow Caledonian University, David has numerous publications in physiology and pharmacology to his name and is a respected opinion leader in the use of human tissue for drug discovery. He chairs the Scottish Lifesciences Association’s special interest group in precision medicine, is a member of the NC3Rs/MHRA working party on human tissues in safety pharmacology and is an advocate for the wider global use of human cells and tissues in drug development.